Evidence map›Paper›PMID 30900486›Full record

ReviewInternational journal of immunopathology and pharmacology

The neuropathic pain: An overview of the current treatment and future therapeutic approaches.

Eugenio Cavalli, Santa Mammana, Ferdinando Nicoletti, Placido Bramanti, Emanuela Mazzon

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04808531 (NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer), which is not on this map. Cited by 268 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
268citing papers in PubMed, 10 pooled it
20.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04808531 phase3unknown statusnot on this map

NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial

TypeinterventionalSponsorMedlab ClinicalRan2023 to 2024Enrolled360ConditionsCancer Related PainArmsNanaBis™, Oxycodone CR, Placebo Spray, Placebo Tablet, Oxycodone IR
3 · Its place in the literature

Who cites it

268 citing papers in PubMed, 10 syntheses or guidelines pooled it, 469 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Neurosurgical management for chronic and end-of-life pain in children: A systematic review.Pain practice : the official journal of World Institute of Pain · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

208 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Eugenio Cavalli1 I.R.C.C.S. Centro Neurolesi Bonino Pulejo, Messina, Italy.
Santa Mammana1 I.R.C.C.S. Centro Neurolesi Bonino Pulejo, Messina, Italy.
Ferdinando Nicoletti2 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Placido Bramanti1 I.R.C.C.S. Centro Neurolesi Bonino Pulejo, Messina, Italy.
Emanuela Mazzon1 I.R.C.C.S. Centro Neurolesi Bonino Pulejo, Messina, Italy.ORCID https://orcid.org/0000-0002-5073-717X
Centro Neurolesi Bonino Pulejo · ITUniversity of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuropathic pain is characterized by abnormal hypersensitivity to stimuli (hyperalgesia) and nociceptive responses to non-noxious stimuli (allodynia). The conditions and the pathophysiological states that determine the onset of neuropathic pain are heterogeneous, such as metabolic disorders, neuropathy caused by viral infections, and autoimmune diseases affecting the central nervous system (CNS). Neuropathic pain in the general population is estimated to have a prevalence ranging between 3% and 17%. Most of the available treatments for neuropathic pain have moderate efficacy and present side effects that limit their use; therefore, other therapeutic approaches are needed for patients. In this article, the current standard of care treatment, the emerging pharmacological approaches from the completed phase III clinical trials, and the preclinical studies on novel promising therapeutic options will be reviewed.

Indexed as

AnalgesicsAnimalsClinical Trials, Phase I as TopicDrug Evaluation, PreclinicalForecastingHumansNeuralgiaPain MeasurementTreatment OutcomeAnalgesicsanimal modelsneuropathic painphase III clinical trialstherapy

Identifiers

PMID30900486
PMCPMC6431761
OpenAlexW2923081322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.